TY - JOUR
T1 - What Does Genetics Tell Us About Age-Related Macular Degeneration?
AU - Grassmann, F
AU - Ach, T
AU - Brandl, C
AU - Heid, IM
AU - Weber, BHF
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Age-related macular degeneration (AMD) is a chronic degenerative disease of the central retina and a major cause of vision impairment and blindness with millions of people affected in the elderly population. In recent years, considerable efforts have been made to understand disease pathology with the long-term goal of designing novel and effective treatment options for this devastating disease. Although striking advances in treating the neovascular stage of late AMD have occurred, no therapy is available for almost half of all AMD patients, specifically those who are affected by the atrophic form of the disease. This review highlights current knowledge on the genetic factors associated with early- and late-stage forms of the disease. It also summarizes the findings regarding the extent to which these factors may play a role in the transition from one disease stage to another, and it emphasizes the need to explore further the underlying mechanisms for both development and progression of this disease as a starting point for designing innovative therapies for it.
AB - Age-related macular degeneration (AMD) is a chronic degenerative disease of the central retina and a major cause of vision impairment and blindness with millions of people affected in the elderly population. In recent years, considerable efforts have been made to understand disease pathology with the long-term goal of designing novel and effective treatment options for this devastating disease. Although striking advances in treating the neovascular stage of late AMD have occurred, no therapy is available for almost half of all AMD patients, specifically those who are affected by the atrophic form of the disease. This review highlights current knowledge on the genetic factors associated with early- and late-stage forms of the disease. It also summarizes the findings regarding the extent to which these factors may play a role in the transition from one disease stage to another, and it emphasizes the need to explore further the underlying mechanisms for both development and progression of this disease as a starting point for designing innovative therapies for it.
UR - http://europepmc.org/abstract/med/28532374
U2 - 10.1146/annurev-vision-082114-035609
DO - 10.1146/annurev-vision-082114-035609
M3 - Article
C2 - 28532374
VL - 1
SP - 73
EP - 96
JO - Annual review of vision science
JF - Annual review of vision science
ER -